New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
16:04 EDTINFIInfinity Pharmaceuticals outlines expected 2013 development milestones
Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride (HCl), a potent and selective Hsp90 inhibitor. Infinity anticipates achieving the following development milestones in 2013:2013: Initiate at least two additional trials in patients with hematologic malignancies 2013: Report additional data from ongoing Phase 1 trial in patients with advanced hematologic malignancies 1H2013: Initiate a Phase 2 trial in patients with rheumatoid arthritis 2H2013: Provide update on Phase 2a trial in patients with mild, allergic asthma
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:07 EDTINFIInfinity Pharma lowers FY15 revenue view to $100M-$120M from $105M-$190M
Consensus is for FY15 revenue $130.6M. Due to changes in the anticipated timing of the initiation of planned clinical studies as well as slower than expected enrollment in DYNAMO+R, Infinity provided the following updated financial guidance for 2015: revenue: Infinity sees FY15 revenue $100M-$120M, compared to prior expectations of $105M-$125M. Sees FY15 net Loss $125M-$145M, compared to prior expectations of $190M-$210M. Sees FY15 cash and Investments balance $230M-$250M, compared to prior expectations of $145M-$165M. This year-end cash and investments includes the $130M milestone payment from AbbVie associated with the completion of patient enrollment in DYNAMO.
October 5, 2015
14:29 EDTINFIInfinity Pharmaceuticals to host research and development day
Subscribe for More Information
September 30, 2015
09:12 EDTINFIInfinity Pharma reaches $130M milestone payment from AbbVie for duvelisib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use